Postmenopausal Osteoporosis Treatment Market
Postmenopausal Osteoporosis Treatment Market Forecasts to 2030 - Global Analysis By Treatment Type (Bisphosphonates, Hormone Replacement Therapy (HRT), Selective Estrogen Receptor Modulators (SERMs), Monoclonal Antibodies, Calcium and Vitamin D Supplements, Anabolic Agents and Other Treatment Types), By Route of Administrations (Oral, Parenteral, Transdermal and Nasal), By Drug Delivery System (Conventional Formulations and Long-Acting Formulations), Patient Demographics, Distribution Channel and By Geography
According to Stratistics MRC, the Global Postmenopausal Osteoporosis Treatment Market is accounted for $8.1 billion in 2023 and is expected to reach $12.6 billion by 2030 growing at a CAGR of 6.6% during the forecast period. Postmenopausal osteoporosis treatment involves medications and lifestyle modifications to mitigate bone loss in women after menopause. Common treatments include bisphosphonates, hormone therapy, and monoclonal antibodies, which aim to strengthen bones and reduce fracture risk. These treatments help maintain bone density, alleviate symptoms and enhance overall bone health.
According to the World Health Organization's October 2021 report, the population of people of age 60 years and more is expected to increase from 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050. According to data published by the International Menopause Society (IMS), in 2021, more than 200 million women are estimated to suffer from osteoporosis, and 1 in 3 women aged more than 50 is expected to experience osteoporosis fracture.
Market Dynamics:
Driver:
The increasing global aging population
With a rising number of individuals entering the postmenopausal phase, there is a subsequent increase in the prevalence of osteoporosis, a condition characterized by reduced bone density and increased fracture risk. This demographic shift creates a growing demand for effective treatment options to address the specific needs of postmenopausal women, fostering research and development initiatives. Pharmaceutical companies are increasingly focusing on developing therapies tailored to this demographic, ranging from innovative drugs to targeted interventions, driving market growth as healthcare systems strive to meet the evolving needs of an aging population susceptible to osteoporosis-related complications.
Restraint:
High treatment costs
The financial burden associated with osteoporosis medications and therapies poses challenges to widespread accessibility and affordability, particularly for patients in regions with limited healthcare resources or inadequate insurance coverage. The cost of osteoporosis treatment often includes not only medication expenses but also diagnostic procedures, monitoring tests, and potential side-effect management, further exacerbating the economic burden on patients. As osteoporosis is a chronic condition requiring long-term management, the cumulative financial impact can dissuade individuals from seeking or continuing treatment.
Opportunity:
Growing awareness regarding the importance of bone health
As awareness grows regarding the risks and consequences of osteoporosis, there is a heightened demand for preventive and therapeutic interventions. Public education campaigns and healthcare initiatives play a pivotal role in encouraging individuals to prioritize bone health, undergo timely screenings, and seek appropriate treatment. This heightened awareness not only fosters early diagnosis but also propels the adoption of osteoporosis treatments, creating a positive market environment where patients are more proactive in managing their bone health and preventing complications associated with postmenopausal osteoporosis.
Threat:
Adverse effects and safety issues
While various pharmaceutical interventions aim to address bone health in postmenopausal women, the potential for adverse reactions may lead to decreased patient compliance and treatment discontinuation. Common side effects such as gastrointestinal disturbances, musculoskeletal pain, and, in some cases, severe complications like atypical fractures or osteonecrosis of the jaw raise concerns among both patients and healthcare providers. These safety issues not only impact the quality of life for affected individuals but also undermine the market's credibility and trust.
Covid-19 Impact:
The COVID-19 pandemic has significantly impacted the market. Lockdowns, disrupted healthcare services, and diverted resources to combat the virus have led to challenges in patient diagnosis and treatment accessibility. Delayed medical appointments and reduced patient visits have affected osteoporosis management. Additionally, supply chain disruptions have impacted drug availability. However, the pandemic has accelerated the adoption of telemedicine and digital health solutions, offering alternative avenues for patient care. The focus on overall healthcare resilience and the importance of preventive measures may influence post-pandemic strategies in managing postmenopausal osteoporosis.
The hormone replacement therapy is expected to be the largest during the forecast period
The hormone replacement therapy segment is expected to have a lucrative growth. In postmenopausal women, reduced estrogen levels result in increased bone resorption, elevating the risk of osteoporosis. HRT involves the administration of estrogen and sometimes progestin to mitigate these effects, promoting bone density maintenance and fracture prevention. Despite proven efficacy, HRT usage is carefully evaluated due to associated risks, such as cardiovascular concerns. Ongoing research focuses on optimizing HRT protocols to maximize benefits while minimizing potential drawbacks in postmenopausal osteoporosis management.
The hospital pharmacies segment is expected to have the highest CAGR during the forecast period
The hospital pharmacies segment is anticipated to witness the fastest CAGR growth during the forecast period. They ensure the availability of prescribed treatments, provide patient education, and facilitate seamless coordination between healthcare professionals and individuals undergoing postmenopausal osteoporosis treatment. Hospital pharmacies contribute to treatment adherence through their expertise in medication management, offering a centralized hub for patients to obtain necessary medications, including emerging and innovative therapies. This integral role underscores their significance in supporting effective healthcare delivery and promoting positive outcomes in the management of postmenopausal osteoporosis.
Region with largest share:
During the forecast period, it is expected that the North American market will continue to hold a majority of the market driven by a substantial aging population and advanced healthcare infrastructure. The region benefits from a high prevalence of postmenopausal osteoporosis, necessitating a robust demand for effective treatments. Technological advancements, well-established pharmaceutical companies, and favorable reimbursement policies contribute to the market's growth. Moreover, ongoing research initiatives and clinical trials in the region focus on innovative therapies, positioning North America as a key hub for the development and commercialization of new and advanced treatments for postmenopausal osteoporosis.
Region with highest CAGR:
Asia Pacific is projected to have the highest CAGR over the forecast period, driven by a growing health-conscious population. The increasing aging population, particularly in countries like Japan and China, contributes to a higher prevalence of osteoporosis, driving the demand for effective treatments. Rising healthcare awareness, improving access to medical facilities, and government initiatives to address women's health issues further propel market expansion. Additionally, collaborations between pharmaceutical companies and healthcare organizations, coupled with advancements in treatment options, are fostering innovation and enhancing the overall landscape for postmenopausal osteoporosis treatment in the Asia Pacific region.
Key players in the market
Some of the key players in Postmenopausal Osteoporosis Treatment market include AbbVie Company (Allergan Pharmaceuticals International Ltd.), Sun Pharmaceutical Industries Ltd., Amgen Inc., BiologicsMD, Chugai Pharma China Co., Ltd. (Roche), Clonz Biotech, Proctor & Gamble Co., Eli Lilly and Company, Enteris BioPharma, Ligand Pharmaceuticals Incorporated., Pfizer Inc., Merck Sharp & Dohme Corp. (Merck & Co., Inc.), Mylan Inc. (Viatris), Oncobiologics, Inc. and Novartis International AG.
Key Developments:
In February 2023, Sandoz received Biologics License Application (BLA) from US Food and Drug Administration (FDA) for a prospective biosimilar of denosumab (Prolia and Xgeva; Amgen). The product is intended for addressing a wide range of conditions, such as osteoporosis in postmenopausal women and in men with an elevated fracture risk, alongside numerous other medical conditions.
In July 2022, Chugai Pharma China Co., Ltd., a subsidiary of Chugai Pharmaceutical Co., Ltd. launched Edirol (eldecalcitol) in China after receiving approval from the China National Medical Products Administration (NMPA) for the treatment of postmenopausal osteoporosis. Edirol is an active vitamin D3 derivative created by Chugai.
Treatment Types Covered:
• Bisphosphonates
• Hormone Replacement Therapy (HRT)
• Selective Estrogen Receptor Modulators (SERMs)
• Monoclonal Antibodies
• Calcium and Vitamin D Supplements
• Anabolic Agents
• Other Treatment Types
Route of Administrations Covered:
• Oral
• Parenteral
• Transdermal
• Nasal
Drug Delivery Systems Covered:
• Conventional Formulations
• Long-Acting Formulations
Patient Demographics Covered:
• Postmenopausal Women
• Elderly Population
Distribution Channels Covered:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Postmenopausal Osteoporosis Treatment Market, By Treatment Type
5.1 Introduction
5.2 Bisphosphonates
5.3 Hormone Replacement Therapy (HRT)
5.4 Selective Estrogen Receptor Modulators (SERMs)
5.5 Monoclonal Antibodies
5.6 Calcium and Vitamin D Supplements
5.7 Anabolic Agents
5.8 Other Treatment Types
6 Global Postmenopausal Osteoporosis Treatment Market, By Route of Administration
6.1 Introduction
6.2 Oral
6.3 Parenteral
6.3.1 Intravenous (IV)
6.3.2 Intramuscular
6.3.3 Subcutaneous
6.4 Transdermal
6.5 Nasal
7 Global Postmenopausal Osteoporosis Treatment Market, By Drug Delivery System
7.1 Introduction
7.2 Conventional Formulations
7.3 Long-Acting Formulations
8 Global Postmenopausal Osteoporosis Treatment Market, By Patient Demographics
8.1 Introduction
8.2 Postmenopausal Women
8.3 Elderly Population
9 Global Postmenopausal Osteoporosis Treatment Market, By Distribution Channel
9.1 Introduction
9.2 Hospital Pharmacies
9.3 Retail Pharmacies
9.4 Online Pharmacies
10 Global Postmenopausal Osteoporosis Treatment Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 AbbVie Company (Allergan Pharmaceuticals International Ltd.)
12.2 Sun Pharmaceutical Industries Ltd.
12.3 Amgen Inc.
12.4 BiologicsMD
12.5 Chugai Pharma China Co., Ltd. (Roche)
12.6 Clonz Biotech
12.7 Proctor & Gamble Co.
12.8 Eli Lilly and Company
12.9 Enteris BioPharma
12.10 Ligand Pharmaceuticals Incorporated.
12.11 Pfizer Inc.
12.12 Merck Sharp & Dohme Corp. (Merck & Co., Inc.)
12.13 Mylan Inc. (Viatris)
12.14 Oncobiologics, Inc.
12.15 Novartis International AG
List of Tables
1 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Region (2021-2030) ($MN)
2 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
3 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Bisphosphonates (2021-2030) ($MN)
4 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Hormone Replacement Therapy (HRT) (2021-2030) ($MN)
5 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2021-2030) ($MN)
6 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
7 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Calcium and Vitamin D Supplements (2021-2030) ($MN)
8 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Anabolic Agents (2021-2030) ($MN)
9 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Other Treatment Types (2021-2030) ($MN)
10 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
11 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Oral (2021-2030) ($MN)
12 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
13 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Intravenous (IV) (2021-2030) ($MN)
14 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Intramuscular (2021-2030) ($MN)
15 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Subcutaneous (2021-2030) ($MN)
16 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Transdermal (2021-2030) ($MN)
17 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Nasal (2021-2030) ($MN)
18 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Drug Delivery System (2021-2030) ($MN)
19 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Conventional Formulations (2021-2030) ($MN)
20 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Long-Acting Formulations (2021-2030) ($MN)
21 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Patient Demographics (2021-2030) ($MN)
22 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Postmenopausal Women (2021-2030) ($MN)
23 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Elderly Population (2021-2030) ($MN)
24 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
25 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
26 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
27 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
